Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Departments of Global Health, Medicine and Epidemiology, University of Washington, Seattle, WA, USA.
Lancet. 2014 Jul 19;384(9939):258-71. doi: 10.1016/S0140-6736(14)60164-1. Epub 2014 Jun 5.
HIV prevalence is increasing worldwide because people on antiretroviral therapy are living longer, although new infections decreased from 3.3 million in 2002, to 2.3 million in 2012. Global AIDS-related deaths peaked at 2.3 million in 2005, and decreased to 1.6 million by 2012. An estimated 9.7 million people in low-income and middle-income countries had started antiretroviral therapy by 2012. New insights into the mechanisms of latent infection and the importance of reservoirs of infection might eventually lead to a cure. The role of immune activation in the pathogenesis of non-AIDS clinical events (major causes of morbidity and mortality in people on antiretroviral therapy) is receiving increased recognition. Breakthroughs in the prevention of HIV important to public health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission, antiretroviral therapy in people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis. Research into other prevention interventions, notably vaccines and vaginal microbicides, is in progress.
HIV 流行率在全球范围内呈上升趋势,因为接受抗逆转录病毒治疗的人寿命延长了,尽管新感染人数从 2002 年的 330 万减少到 2012 年的 230 万。全球与艾滋病相关的死亡人数在 2005 年达到 230 万的峰值,到 2012 年降至 160 万。到 2012 年,估计有 970 万人在低收入和中等收入国家开始接受抗逆转录病毒治疗。对潜伏感染机制和感染储存库重要性的新认识可能最终导致治愈。免疫激活在非艾滋病临床事件(接受抗逆转录病毒治疗者发病率和死亡率的主要原因)发病机制中的作用越来越受到重视。对公共卫生至关重要的 HIV 预防方面的突破包括男性医疗性割礼、抗逆转录病毒药物预防母婴传播、HIV 感染者的抗逆转录病毒治疗以预防传播,以及抗逆转录病毒药物的暴露前预防。正在进行其他预防干预措施的研究,特别是疫苗和阴道杀微生物剂。